Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Incyte Corp
(NQ:
INCY
)
64.12
-1.62 (-2.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,033,047
Open
65.97
Bid (Size)
63.97 (2)
Ask (Size)
65.55 (1)
Prev. Close
65.74
Today's Range
64.06 - 65.97
52wk Range
50.27 - 70.36
Shares Outstanding
222,430,635
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
September 18, 2024
Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-selling drug, faces potential revenue decline amid generic competition. Truist...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Wall Street Lower Ahead Of Interest Rate Move
September 18, 2024
Stocks are slightly lower this afternoon, as investors hope for the Federal Open Market Committee (FOMC) to issue its first interest rate cut in four years later today.
Via
Talk Markets
Performance
YTD
-2.03%
-2.03%
1 Month
-0.03%
-0.03%
3 Month
+0.58%
+0.58%
6 Month
+11.55%
+11.55%
1 Year
+9.14%
+9.14%
More News
Read More
Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers
September 16, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
September 14, 2024
From
Incyte
Via
Business Wire
Incyte Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
September 03, 2024
Via
Benzinga
Analyst Expectations For Incyte's Future
August 15, 2024
Via
Benzinga
Analyst Ratings For Incyte
July 26, 2024
Via
Benzinga
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
September 14, 2024
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 09, 2024
From
Incyte
Via
Business Wire
Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
August 21, 2024
From
Incyte
Via
Business Wire
Looking for growth without the hefty price tag? Consider NASDAQ:INCY.
July 22, 2024
Via
Chartmill
Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study
August 16, 2024
Via
Benzinga
Exposures
Product Safety
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma
August 15, 2024
From
Incyte
Via
Business Wire
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
August 15, 2024
Via
Benzinga
Exposures
Product Safety
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
August 14, 2024
From
Incyte and Syndax Pharmaceuticals
Via
Business Wire
Incyte to Present at Upcoming Investor Conferences
August 13, 2024
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2024
From
Incyte
Via
Business Wire
After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial
July 31, 2024
Via
Benzinga
Topics
Death
Exposures
Death
Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance
July 30, 2024
Via
Benzinga
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
July 30, 2024
From
Incyte
Via
Business Wire
NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
July 10, 2024
Via
Chartmill
S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday?
July 09, 2024
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Incyte to Report Second Quarter Financial Results
July 09, 2024
From
Incyte
Via
Business Wire
The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024
July 09, 2024
Via
InvestorPlace
7 Cheap Biotech Stocks With Major Upside Potential
July 09, 2024
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.